ES2162992T3 - Uso de 3-alfa-hidroxi-5-alfa-androsta-16-eno como medicamento. - Google Patents

Uso de 3-alfa-hidroxi-5-alfa-androsta-16-eno como medicamento.

Info

Publication number
ES2162992T3
ES2162992T3 ES96402710T ES96402710T ES2162992T3 ES 2162992 T3 ES2162992 T3 ES 2162992T3 ES 96402710 T ES96402710 T ES 96402710T ES 96402710 T ES96402710 T ES 96402710T ES 2162992 T3 ES2162992 T3 ES 2162992T3
Authority
ES
Spain
Prior art keywords
alfa
androsta
hidroxi
eno
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96402710T
Other languages
English (en)
Inventor
Daniel Philibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2162992T3 publication Critical patent/ES2162992T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE AL SIGUIENTE COMPUESTO: ASI COMO A SUS ESTERES FARMACEUTICAMENTE ACEPTABLES, COMO MEDICAMENTOS PARTICULARMENTE DESTINADOS A PREVENIR Y/O A TRATAR CIERTAS FORMAS DE ESTERILIDAD MASCULINA ASOCIADAS AL PODER DE FECUNDACION INSUFICIENTE DE LOS ESPERMATOZOIDES, ASI COMO LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ES96402710T 1995-12-13 1996-12-12 Uso de 3-alfa-hidroxi-5-alfa-androsta-16-eno como medicamento. Expired - Lifetime ES2162992T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9514750A FR2742337B1 (fr) 1995-12-13 1995-12-13 Application du 3-alpha-hydroxy-5-alpha-androsta-16-ene a titre de medicaments

Publications (1)

Publication Number Publication Date
ES2162992T3 true ES2162992T3 (es) 2002-01-16

Family

ID=9485442

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96402710T Expired - Lifetime ES2162992T3 (es) 1995-12-13 1996-12-12 Uso de 3-alfa-hidroxi-5-alfa-androsta-16-eno como medicamento.

Country Status (9)

Country Link
US (1) US5696107A (es)
EP (1) EP0779075B1 (es)
JP (1) JPH09176183A (es)
AT (1) ATE207750T1 (es)
DE (1) DE69616484T2 (es)
DK (1) DK0779075T3 (es)
ES (1) ES2162992T3 (es)
FR (1) FR2742337B1 (es)
PT (1) PT779075E (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR676202A (fr) * 1928-06-06 1930-02-20 Serrure à pène applicable aux portes fermant à gauche et à droite
US5155045A (en) * 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
EP0209590A1 (en) * 1985-01-25 1987-01-28 Monell Chemical Senses Center The use of male essence, including androstenol and dehydroepiandrosterone sulfate to treat luteal phase defects and failure to ovulate in human females
JPH01115892A (ja) * 1987-10-29 1989-05-09 Mitsubishi Electric Corp 液相成長装置
US5272134A (en) * 1992-03-24 1993-12-21 Erox Corporation Fragrance compositions and other compositions which contain human pheromones
FR2717690B1 (fr) * 1994-03-24 1996-04-26 Roussel Uclaf Application de stéroïdes aromatiques 3 substitués par un aminoalcoxy substitué à l'obtention d'un médicament pour contrôler la stérilité, notamment masculine.
WO1996036230A1 (en) * 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulators for new members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
EP0779075B1 (fr) 2001-10-31
FR2742337A1 (fr) 1997-06-20
JPH09176183A (ja) 1997-07-08
ATE207750T1 (de) 2001-11-15
FR2742337B1 (fr) 1998-03-06
DK0779075T3 (da) 2002-02-18
PT779075E (pt) 2002-04-29
EP0779075A1 (fr) 1997-06-18
DE69616484D1 (de) 2001-12-06
US5696107A (en) 1997-12-09
DE69616484T2 (de) 2002-04-04

Similar Documents

Publication Publication Date Title
ATE494009T1 (de) Prodrugs, ihre herstellung und verwendung als arzneimittel
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
ES1022219Y (es) "ambientador de sobremesa"
PT929565E (pt) Esteres de nitrato de compostos corticoides e suas aplicacoes farmaceuticas
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
ITMI940884A0 (it) Medicamento topico ad attivita' cicatrizzante
DE68927055D1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
ES2162992T3 (es) Uso de 3-alfa-hidroxi-5-alfa-androsta-16-eno como medicamento.
ES2129053T3 (es) Nuevos derivados de fosfolipidos.
DK0487613T3 (da) Megakarycytopiesk faktor
NO933235D0 (no) Anvendelse av en inhibitor for fremstilling av et medikament
AU7649891A (en) Heterocyclic-nmda antagonists
CS318690A3 (en) Pharmaceutical composition usable for depression therapy
DE68906437D1 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti-cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.
UA25976C2 (uk) Противиразковий лікарський препарат
UA15909A1 (uk) Засіб лікуваhhя хроhічhих паhкреатитів
ECSP951483A (es) Heteroaril--oxazolidinonas de 5 eslabones que contienen nitrogeno

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 779075

Country of ref document: ES